The board of directors forms a knowledgeable and entrepreneurial team.
Dr. Pieter J. Gaillard graduated as a neuroscientist at Utrecht University in the Netherlands and obtained a PhD in pharmacology from Leiden University in 2000, after which he successfully conducted six rounds of equity investments, ranging from seed to series C venture capital, as well as numerous non-dilutive credits and grants. During this tenure, Pieter either invented or licensed-in the patents held by the company, and led the company through the discovery and (pre)clinical phases of drug development. Subsequently, he licensed-out the company’s brain cancer program to a Danish company, established a joint venture in Taiwan around the acute MS relapse program, and co-created a German company focused on treating inherited retinal degenerative diseases.
The other directors are three investors who amongst them share a wealth of entrepreneurial experience. They all have a close bond with the health care sector, originating from their academic education or developed from past co-investments in health care companies.